See up to 3 months of EXEL. The 7-day demo opens the 1M and 3M ranges and puts EXEL on your watchlist.
Start 7-day demoLatest EXEL insider trades
Mary C. Beckerle - DirectorOpen-market sale$527K- Jack L. Wyszomierski - DirectorOpen-market sale$198K
About EXELIXIS, INC. (EXEL)
EXELIXIS, INC. is an SEC registrant, filing under CIK 0000939767, classified as biological products (no diagnostic substances). It is grouped with Health Care companies on this site.
EXEL Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 9,812 | $527K |
EXEL insider transactions (Form 4)
3977 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mary C. Beckerle - Director | Open-market sale | Common Stock | 9,812 | $53.66 footnote F2 | $527K | |
| ||||||
| Jack L. Wyszomierski - Director | Open-market sale | Common Stock | 3,925 | $50.55 | $198K | |
| Sue Gail Eckhardt - Director | Open-market sale | Common Stock | 9,812 | $50.14 footnote F2 | $492K | |
| ||||||
| Stelios Papadopoulos - Director | Grant or award | Common Stock | 8,367 footnote F1 | $0.00 | - | |
| ||||||
| Tomas J. Heyman - Director | Grant or award | Common Stock | 8,367 footnote F1 | $0.00 | - | |
| ||||||
| Sue Gail Eckhardt - Director | Grant or award | Common Stock | 8,367 footnote F1 | $0.00 | - | |
| ||||||
| Julie Smith - Director | Grant or award | Common Stock | 8,367 footnote F1 | $0.00 | - | |
| ||||||
 Maria C. Freire - Director | Grant or award | Common Stock | 8,367 footnote F1 | $0.00 | - | |
| ||||||
| Mary C. Beckerle - Director | Grant or award | Common Stock | 8,367 footnote F1 | $0.00 | - | |
| ||||||
| Bob Oliver - Director | Grant or award | Common Stock | 8,367 footnote F1 | $0.00 | - | |
| ||||||
| Jack L. Wyszomierski - Director | Grant or award | Common Stock | 8,367 footnote F1 | $0.00 | - | |
| ||||||
| George Poste - Director | Grant or award | Common Stock | 8,367 footnote F1 | $0.00 | - | |
| ||||||
| David Edward Johnson - Director | Grant or award | Option (right to buy) | 19,133 | $0.00 | - | |
 Dana Aftab - Officer | Open-market sale | Common Stock | 43,451 | $50.35 | $2.19M | |
| Patrick J. Haley - Officer | Open-market sale | Common Stock | 32,110 | $49.81 footnote F1 | $1.60M | |
| ||||||
| Michael Morrissey - Officer | Tax withholding / forfeiture | Common Stock | 128,497 footnote F1 | $51.10 | $6.57M | |
| Michael Morrissey - Officer | Gift | Common Stock | 124,047 footnote F3 | $0.00 | - | |
| Michael Morrissey - Officer | Gift | Common Stock | 124,047 footnote F3 | $0.00 | - | |
| ||||||
| Christopher J. Senner - Officer | Tax withholding / forfeiture | Common Stock | 40,892 footnote F1 | $51.10 | $2.09M | |
| Christopher J. Senner - Officer | Open-market sale | Common Stock | 34,901 | $50.00 footnote F3 | $1.75M | |
| ||||||
| Patrick J. Haley - Officer | Tax withholding / forfeiture | Common Stock | 33,265 footnote F1 | $51.10 | $1.70M | |
| ||||||
| Brenda Hefti - Officer | Tax withholding / forfeiture | Common Stock | 6,411 footnote F1 | $51.10 | $328K | |
| Brenda Hefti - Officer | Open-market sale | Common Stock | 6,625 | $50.21 footnote F4 | $333K | |
| ||||||
| Dana Aftab - Officer | Tax withholding / forfeiture | Common Stock | 30,578 footnote F1 | $51.10 | $1.56M | |
| ||||||
| Mary C. Beckerle - Director | Option exercise | Common Stock | 3,856 | $23.24 | $90K | |
| Mary C. Beckerle - Director | Open-market sale | Common Stock | 7,712 | $48.45 | $374K | |
| Mary C. Beckerle - Director | Option exercise | Option (right to buy) | 3,856 | $0.00 | - | |
| Maria C. Freire - Director | Option exercise | Common Stock | 20,634 | $19.77 | $408K | |
| Maria C. Freire - Director | Open-market sale | Common Stock | 20,634 | $46.00 | $949K | |
| Maria C. Freire - Director | Option exercise | Option (right to buy) | 20,634 | $0.00 | - | |
| George Poste - Director | Open-market sale | Common Stock | 60,000 | $45.71 footnote F1 | $2.74M | |
| ||||||
| Michael Morrissey - Officer | Gift | Common Stock | 109,676 | $0.00 | - | |
| Dana Aftab - Officer | Grant or award | Common Stock | 52,018 footnote F1 | $0.00 | - | |
| ||||||
| Christopher J. Senner - Officer | Grant or award | Common Stock | 52,018 footnote F1 | $0.00 | - | |
| ||||||
| Brenda Hefti - Officer | Grant or award | Common Stock | 23,119 footnote F1 | $0.00 | - | |
| ||||||
| Patrick J. Haley - Officer | Grant or award | Common Stock | 40,459 footnote F1 | $0.00 | - | |
| ||||||
| Michael Morrissey - Officer | Gift | Common Stock | 100,278 | $0.00 | - | |
| Michael Morrissey - Officer | Grant or award | Common Stock | 160,437 footnote F3 | $0.00 | - | |
| ||||||
| Dana Aftab - Officer | Open-market sale | Common Stock | 47,918 | $44.50 | $2.13M | |
Item 8.01
Item 8.01
Item 2.02, 9.01
Item 5.02, 5.07, 9.01
Recent EXEL Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| MARY BECKERLE | Director | 9,812 | $526K | View on EDGAR | |
| - | - | - | - |
EXEL insider trading FAQ
What is the latest insider trade for EXEL?
EXELIXIS, INC. (EXEL) had 1 insider filing in the last 90 days, with the most recent on 2026-08-12. The full record for EXEL runs to 77 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying EXEL stock?
No insider purchases of EXEL were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling EXEL stock?
1 insider sale of EXEL was filed in the last 90 days, totaling $527K.
Where can I see EXEL SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects EXEL Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Mary C. Beckerle view on EDGAR
- - Jack L. Wyszomierski view on EDGAR
- - Sue Gail Eckhardt view on EDGAR
- - Stelios Papadopoulos view on EDGAR
- - Tomas J. Heyman view on EDGAR
- - Sue Gail Eckhardt view on EDGAR
- - Julie Smith view on EDGAR
- - Maria C. Freire view on EDGAR
- - Mary C. Beckerle view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where EXEL's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow EXEL with a 7-day demo
- EXEL on your watchlist
- Every EXEL Form 4 filing on record
- Up to 3 months of EXEL price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
